End-of-day quote
Shanghai S.E.
06:00:00 2024-05-23 pm EDT
|
5-day change
|
1st Jan Change
|
5.95
CNY
|
-3.41%
|
|
-6.74%
|
-44.81%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
6,412
|
6,145
|
3,392
|
-
|
-
|
Enterprise Value (EV)
1 |
6,412
|
6,145
|
3,392
|
3,392
|
3,392
|
P/E ratio
|
-26.2
x
|
-15.4
x
|
-9.44
x
|
-10.1
x
|
-14.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
245,690
x
|
447
x
|
32.3
x
|
11.2
x
|
5.62
x
|
EV / Revenue
|
245,690
x
|
447
x
|
32.3
x
|
11.2
x
|
5.62
x
|
EV / EBITDA
|
-27.7
x
|
-15.7
x
|
-9.09
x
|
-10.8
x
|
-19.2
x
|
EV / FCF
|
-
|
-12.3
x
|
-7.35
x
|
-6.28
x
|
-6.43
x
|
FCF Yield
|
-
|
-8.13%
|
-13.6%
|
-15.9%
|
-15.6%
|
Price to Book
|
2.31
x
|
2.57
x
|
1.67
x
|
2
x
|
2.33
x
|
Nbr of stocks (in thousands)
|
570,000
|
570,000
|
570,000
|
-
|
-
|
Reference price
2 |
11.25
|
10.78
|
5.950
|
5.950
|
5.950
|
Announcement Date
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.0261
|
13.75
|
105
|
301.5
|
603.5
|
EBITDA
1 |
-
|
-231.5
|
-390.8
|
-373
|
-315
|
-177
|
EBIT
1 |
-
|
-247.6
|
-404
|
-363
|
-337
|
-243
|
Operating Margin
|
-
|
-948,479.31%
|
-2,937.5%
|
-345.71%
|
-111.77%
|
-40.27%
|
Earnings before Tax (EBT)
1 |
-
|
-245.3
|
-401.5
|
-360
|
-335
|
-241
|
Net income
1 |
-238.4
|
-246.6
|
-400.4
|
-359
|
-334
|
-240
|
Net margin
|
-
|
-944,803.1%
|
-2,911.55%
|
-341.9%
|
-110.78%
|
-39.77%
|
EPS
2 |
-0.5200
|
-0.4300
|
-0.7000
|
-0.6300
|
-0.5900
|
-0.4200
|
Free Cash Flow
1 |
-
|
-
|
-499.8
|
-461.7
|
-539.6
|
-527.8
|
FCF margin
|
-
|
-
|
-3,634.19%
|
-439.75%
|
-178.98%
|
-87.46%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-500
|
-462
|
-540
|
-528
|
ROE (net income / shareholders' equity)
|
-
|
-8.53%
|
-15.5%
|
-17.7%
|
-19.7%
|
-16.5%
|
ROA (Net income/ Total Assets)
|
-
|
-8.26%
|
-14.5%
|
-16%
|
-17.2%
|
-11.2%
|
Assets
1 |
-
|
2,986
|
2,756
|
2,244
|
1,942
|
2,143
|
Book Value Per Share
2 |
-
|
4.860
|
4.190
|
3.560
|
2.970
|
2.550
|
Cash Flow per Share
2 |
-
|
-0.4200
|
-0.7000
|
-0.9600
|
-
|
-
|
Capex
1 |
-
|
26.6
|
102
|
37
|
163
|
160
|
Capex / Sales
|
-
|
101,955.75%
|
738.98%
|
35.24%
|
53.9%
|
26.51%
|
Announcement Date
|
2/24/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Last Close Price
5.95
CNY Average target price
12.28
CNY Spread / Average Target +106.47% Consensus |
1st Jan change
|
Capi.
|
---|
| -44.81% | 468M | | +12.30% | 118B | | +12.15% | 106B | | -8.14% | 23.4B | | -1.16% | 21.78B | | -9.37% | 18.09B | | -41.25% | 16.72B | | -15.33% | 15.97B | | +5.80% | 14.03B | | +28.03% | 11.67B |
Bio Therapeutic Drugs
|